Not checkedNot checked for notices yet.
Cancer Testis Antigens and Immunotherapy: A new Dawn
Zhang Bingcan
E3S Web of Conferences · 2021
doi:10.1051/e3sconf/202125102033 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Immunotherapy for cancer has been recognized as the fourth therapeutic method after surgery, radiotherapy and chemotherapy, which can prevent postoperative metastasis and recurrence and reduce or even eliminate the toxic and side effects of chemoradiotherapy. The development of successful immunotherapy strategies need to use cancer antigens which can be identified by the host’s immune system. This method’s ability in causing antitumor immune response has been fully proved, but it also faces enormous risks and challenges, as finding the highly efficient and specific tumor markers is very difficult. Cancer-testis antigens(CTA) are a special kind of tumor antigens with normal expression restricted to male germ cells in the testis but not in adult somatic tissues. The immune privileged status of CTA gives tumor specificity and makes it an ideal candidate for targeted immunotherapy biomarkers. Here, we briefly review the research history, expression characteristics of CTA, molecular mechanisms of CT gene, and the bright future of immunotherapy in cancer treatment.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.